CABL001A2301 (R/R)

CABL001A2301 (R/R)

A phase 3, multicenter, open-label, randomized study of oral ABL001 versus bosutinib in patients with chronic myelogenous leukemia in chronic phase (CML-CP), previously treated with 2 or more tyrosine kinase inhibitors


Study treatments

Experimental arm
ABL001 40mg tablets will be taken orally twice a day
Active comparator
Bosutinib 500mg tablets will be taken orally once daily


Inclusion criteria


Exclusion criteria


Participating sites






Link